muscular dystrophy, progressive Pectorodorsal

Summary

muscular dystrophy, progressive Pectorodorsal (MONDO:0010678) is a disease. A subtype of muscular dystrophy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	muscular dystrophy, progressive Pectorodorsal
Mondo ID	MONDO:0010678
MeSH	C564095
OMIM	310095
UMLS	C1839669
MedGen	326550
GARD	0024748
Is cancer (heuristic)	no

Also known as: muscular dystrophy, progressive Pectorodorsal

Disease family

This is a subtype of muscular dystrophy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › muscle tissue disorder › skeletal muscle disorder › myopathy › muscular dystrophy › muscular dystrophy, progressive Pectorodorsal

Related subtypes (10): muscular dystrophy, Barnes type, muscular dystrophy, cardiac type, muscular dystrophy, Hemizygous lethal type, muscular dystrophy, Mabry type, progressive muscular dystrophy, distal myopathy, congenital muscular dystrophy, Fukuda-Miyanomae-Nakata syndrome, LAMA2-related muscular dystrophy, DMD-related muscular dystrophy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.